SYRS (Syros Pharmaceuticals) Cyclically Adjusted PS Ratio: (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SYRS Syros Pharmaceuticals Inc SYRS
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Syros Pharmaceuticals  (OTCPK:SYRS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Syros Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Syros Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Syros Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syros Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SYRS vs AFMDQ, BTAX, TRVN: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Syros Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


SYRS
12GF Score
Syros Pharmaceuticals Inc SYRS
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Syros Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Syros Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0/315.3010*315.3010
=0.000

Current CPI (Sep. 2024) = 315.3010.

Syros Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.000 234.812 0.000
201503 0.000 236.119 0.000
201506 1.243 238.638 1.642
201509 0.000 237.945 0.000
201512 0.000 236.525 0.000
201603 0.000 238.132 0.000
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 0.136 241.432 0.178
201703 0.471 243.801 0.609
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 0.000 246.524 0.000
201803 0.122 249.554 0.154
201806 0.114 251.989 0.143
201809 0.122 252.439 0.152
201812 0.265 251.233 0.333
201903 0.134 254.202 0.166
201906 0.111 256.143 0.137
201909 0.131 256.759 0.161
201912 0.118 256.974 0.145
202003 0.542 258.115 0.662
202006 0.698 257.797 0.854
202009 0.836 260.280 1.013
202012 1.168 260.474 1.414
202103 0.786 264.877 0.936
202106 0.821 271.696 0.953
202109 0.905 274.310 1.040
202112 1.239 278.802 1.401
202203 0.867 287.504 0.951
202206 0.983 296.311 1.046
202209 0.413 296.808 0.439
202212 -0.037 296.797 -0.039
202303 0.106 301.836 0.111
202306 0.101 305.109 0.104
202309 0.134 307.789 0.137
202312 0.013 306.746 0.013
202403 0.000 312.332 0.000
202406 0.000 314.175 0.000
202409 0.000 315.301 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
12GF Score

Get the complete analysis for SYRS

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price